Sanofi invests $700M in Alnylam's RNAi tech; Merck drops RNAi specialist Sirna;

> Sanofi ($SNY) invested $700 million in Alnylam's ($ALNY) RNAi technology. Story

> Merck ($MRK) sold Sirna Therapeutics, its RNAi arm, to Alnylam ($ALNY). Article

> Researchers at the University of North Carolina have come up with a new way to visualize RNA, an advancement that could have future implications for drug delivery. More

> Interface Biologics and Q3 Medical Devices signed an agreement to develop a drug-coated balloon with Interface's Kinesyx technology. Release

Suggested Articles

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.

Genentech's Port Delivery System with ranibizumab matched Lucentis eye injections in a late-stage, wet age-related macular degeneration trial.

Honeywell aims to wean the industry of its glass habit with Aclar Edge, a new line of bottles and vials made with the company's patented plastic.